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The objective of the study was determining the prophylactic effect of Lactobacillus casei IMV B-7280, L. acidophilus IMV B-
7279, L. delbrueckii subsp. bulgaricus IMV B-7281, Bifidobacterium animalis VKL and B. animalis VKB probiotic strains on expe-
rimental vaginitis in BALB/c mice induced by Staphylococcus aureus 8325-4. The infection with S. aureus 8325-4 caused an imbal-
ance of microbiota in the vagina and intestine, as evidenced by an increase in the number of opportunistic microorganisms and a 
decrease in the amount of lactobacilli and bifidobacteria. L. casei IMV B-7280, B. animalis VKL and B. animalis VKB probiotic 
strains altered the microbiota spectrum of the vagina and intestine of Staphylococcus-infected mice: the amount of Lactobacillus and 
bifidobacteria increased with the reduction of the number of opportunistic microorganisms. Also under the influence of these strains, 
the normalization of the microbiota spectrum typical for vagina and intestine was observed in different periods of observation – in the 
intestines of mice the number of coliform bacteria increased, the number of microscopic fungi, streptococci and staphylococci de-
creased; in the vagina, the number of coliform bacteria and microscopic fungi decreased, the number of streptococci normalized. 
Rapid elimination of S. aureus 8325-4 from the vagina and prevention of the spread of infection to the intestine were observed after 
use of probiotics. Preventive effect of L. acidophilus IMV B-7279 and L. delbrueckii subsp. bulgaricus IMV B-7281 for bacterial 
vaginitis in mice was less effective. So, the target probiotic strains L. casei IMV B-7280, B. animalis VKL and B. animalis VKB are 
promising for the creation of highly effective novel probiotic drugs that can be used for directed prevention of infectious and inflam-
matory diseases of the genitourinary system caused by pathogenic and opportunistic microorganisms.  
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Introduction  
 
Development and improvement of means for the prevention and 
treatment of genitourinary system infectious diseases caused by patho-
genic and opportunistic bacteria, viruses and microscopic fungi are 
some of the priority public health needs. Despite the constant increase in 
the number of antibiotics and antiviral drugs and expansion of their 
spectrum of action and therapeutic efficacy, the number of infectious 
diseases of the genitourinary system, according to statistics, not only 
does not decrease, but on the contrary rapidly increases (Kenyon & 
Osbak, 2014). In addition, in recent years, a significant increase in the 
number of chronic and recurrent infections of the genitourinary system, 
the occurrence of concomitant pathologies in the form of dysbiotic 
disorders or the accession of other pathogens to the primary infectious 
process were noted (Cianci et al., 2018).  
Frequent recurrent uncomplicated urinary tract infections, which 
arise primarily in patients with immunosuppression who received high 
doses of immunosuppressive drugs, antibiotics, hormones, irradiation with 
radiotherapy etc., can be a cause of serious illness that involves not only 
organs of genitourinary system, but the organism as a whole. So, pro-
longed bacterial vaginosis caused by opportunistic bacteria is associated 
with a high risk of developing of infectious diseases, infertility, autoim-
mune and neuroendocrine diseases, and may increase the risk of late 
miscarriage (Martin et al., 1999; Schwebke, 2003; Hay, 2004).  
Combined therapy of patients with bacterial vaginitis and urinary 
system infections including, in particular, the use of antibiotics, resulted 
in more disorders of the natural balance of microbiota of various cavi-
ties and leads to the "vicious circle" of constantly recurrent infectious 
pathologies and of new courses of antibiotic therapy. In addition, the 
widespread use of chemotherapeutic agents of various origins, including 
the newest antibiotics, has led to the selection of resistant strains of 
opportunistic microorganisms (Podgorskij et al., 2004). Therefore, at the 
present stage, the use of complex antibiotic therapy with the simultane-
ous treatment of patients with several antibacterial agents with different 
mechanisms of action gradually is being introduced to the therapeutic 
practice, which has negative consequences not only for microbiota of 
different body cavities, but also for organs and systems of macroorganism.  
Therefore, the development of alternative means for prevention and 
treatment of patients with uncomplicated urinary tract infections and 
vaginosis that involve the use of natural products with an antagonistic 
effect on infectious agents and the ability to balance the immune re-
sponse is relevant. Such means are the latest probiotic preperetions, 
created on the basis of representatives of normal microbiota – non-pa-
thogenic lactic acid bacteria with antibacterial, anti-inflammatory and 
immunomodulatory properties (Reid, 2001; MacPhee et al., 2013).  
Previously we found that Lactobacillus acidophilus IMV B-7279, 
L. delbrueckii subsp. bulgaricus IMV B-7281, L. casei IMV B-7280, 
Bifidobacterium animalis VKL and B. animalis VKB probiotic strains 
have a wide range of antagonistic effects against pathogenic and oppor-
tunistic microorganisms in vitro and in vivo, as well as immunomodula-
tory and anti-inflammatory properties aimed at changing the cytokine 
profile of organism and activating the factors of innate immune respon-
se (Lazarenko et al., 2012; Babenko et al., 2015). Probiotic strains L. 
casei IMV B-7280, B. animalis VKL and B. animalis VKB had an ef-
fective curative effect on the model of bacterial vaginitis of BALB/c 
line mice: under their influence, the elimination of pathogenic and op-
portunistic bacteria from the vagina, kidneys and intestinal contents was 
observed. In these mice we detected normalization of microbiota of 
different biotopes, as well as indicators of immunoreactivity (activity of 
phagocytic system cells, cellular immunity indexes and production of 
cytokines – interferon-γ, interleukin (IL)-12, IL-4) (Мokrozub et al., 
2015; Lazarenko et al., 2017). However, the potential prophylactic effect 
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of probiotic strains of lactobacilli and bifidobacteria and their ability to 
prevent the development of bacterial infection of the genitourinary sys-
tem was not identified.  
The novelty of this study is to implement the latest approaches to 
the production of probiotic preparations based on the representatives of 
commensal microbiota of different biotopes with simultaneously decla-
red antibacterial, immunomodulatory and anti-inflammatory properties 
for the prevention of infectious and inflammatory diseases and treat-
ment of patients. Therefore, the objective of this work was determining 
the prophylactic action of L. casei IMV В-7280, L. аcidophilus IMV В-
7279, L. delbrueckii subsp. bulgaricus IMV B-7281, B. animalis VKL 
and B. animalis VKB probiotic strains in case of experimental vaginitis 
in BALB/c line mice induced by Staphylococcus aureus 8325-4.  
 
Materials and methods  
 
Objects of the study were five potentially probiotic strains of the 
genus Lactobacillus and Bifidobacterium, such as L. casei IMV В-7280, 
L. acidophilus IMV В-7279, L. delbrueckii subsp. bulgaricus IMV В-7281, 
B. animalis VKL and B. animalis VKB. These strains were previously 
isolated from clinically healthy donors from associated cultures during 
laboratory studies of fermented biological material. The bacteria that 
freeze dried using the Cuddon Freeze Dryer FD1500 (New Zealand). 
Before each experiment, the viability of strains was checked by control-
ling their growth on selective media for lactobacilli – Man-Rogosa-
Sharpe (MRS) and bifidobacteria – Bifido Agar (BA) ("Merck", Ger-
many) at 37 °C for 24–48 hours in aerobic and anaerobic conditions, 
respectively. In this work, the probiotic preparation Labilact® (SPA 
Ariadna, Odessa, Ukraine), which includes a mixture of freeze-dried 
strains of lactobacilli and bifidobacteria, placed in the capsule for intra-
vaginal administration, was used for comparison.  
Experimental studies were carried out on female mice of the 
BALB/c line of 6–8 weeks old, 17–22 g weight, synchronized accor-
ding to the estral cycle. The animals were kept in standard conditions in 
plastic cells in a separate room at a constant air temperature (22–25 ºС). 
The animals received a good meal and had free access to water. Before 
the experiment, all animals were kept at quarantine for two weeks and 
had no signs of the disease. All studies were conducted taking into ac-
count the norms of the European Convention for the protection of ver-
tebrate animals used for experimental and other scientific purposes 
(18.03.1986, Strasbourg) and the Law of Ukraine No. 3447-IV "On the 
Protection of Animals from Cruel Treatment" (Reznіkov, 2001).  
Animals were randomly assigned to groups of 15 individuals in 
each (n = 15). A suspension of probiotic bacteria (each strain individual-
ly) in 0.15 M NaCl was injected into vagina in the volume of 0.025 mL 
and the dose of 5 x 106 cells/animal once per day during 7 days. Under 
the same scheme, a separate group of mice was intravaginally adminis-
tered with the Labilact® probiotic preparation. The control group in-
cluded intact mice receiving 0.15 M NaCl intravaginally.  
In order to simulate vaginitis in mice we used Staphylococcus aureus 
strain 8325-4. This strain was grown on a selective medium for staphy-
lococci BAIRD-PARKER-Agar (Merck, Germany) at 37 °C for 
24 hours. Daily culture of S. aureus 8325-4 in suspension with 0.15 M 
NaCl was administered into vagina of mice in a dose of 5 x 107 cells per 
animal after completing the course of prophylactic administration of 
probiotic strains. S. aureus 8325-4 contains the plasmid of resistance to 
gentamicin, therefore it can be separated from other microorganisms on 
the growth medium containing this antibiotic (15 μg/mL).  
Vaginal discharges were collected on the 1st, 3rd, 6th, 9th and 12th 
days after infecting mice using standard sterile cotton swabs that were 
placed in test tubes containing 1 mL of sterile 0.15 M NaCl. At the 
same time, feces were collected, weighed, placed in a test tube and filled 
with a volume of 0.15 M NaCl to form a suspension of 0.1 g of feces 
per mL (De Jongh et al., 1968).  
To determine the spectrum of microbiota, aliquots from the vagina 
and feces were plated on eight nutrient media, namely: meat-peptone 
agar (MPA) – medium for cultivation of aerobic and optional anaerobic 
microorganisms; BAIRD-PARKER-Agar (Merck, Germany) – selec-
tive medium for staphylococci; BAIRD-PARKER-Agar with gentami-
cin in concentration of 15 μg/mL – selective medium for isolation of S. 
aureus 8325-4 strain; KF-Streptococcus agar (Merck, Germany) – 
selective medium for streptococci, MRSA (HiMedia, India) – selective 
medium for lactobacilli; BA (HiMedia, India) – selective medium for 
bifidobacteria; ENDO (HiMedia, India) – selective medium for coli-
form bacteria; Sabouraud agar (HiMedia, India) – selective medium for 
microscopic fungi. After cultivation at 37 °C for 24 hours, the number 
of colonies per petri dish was calculated, given that one such colony 
was grown out of one bacterium (Brown & Perry, 1992).  
All biological material, as well as all the tools and laboratory uten-
sils used during the research, were decontaminated by autoclaving. 
Remains of animals were utilized in accordance with the recommenda-
tions (Niwayama, 1971).  
All received digital data were processed using the computer pro-
gram Epi Info (version 8.0) by the method of variation statistics. Nu-
merical data was presented in the form of arithmetic average and stan-
dard deviations (x ± SD). Null hypothesis for the comparison groups 
was verified using non-parametric Wilcoxon-Mann-Whitney (U) and 
Kolmogorov-Smirnov criteria. Differences between the groups were 
considered statistically significant at P < 0.05.  
 
Results  
 
Microbiota of the vagina of mice that received probiotic strains 
intravaginally as a prophylactic. In the vagina of infected mice that did 
not receive probiotic strains of bacteria (control group) S. aureus 8325-4 
was detected in a constant amount throughout the observation period 
(Fig. 1). At the same time from the vagina of infected mice that received 
probiotic strains of bacteria S. aureus 8325-4 were collected in a smaller 
quantity. It was completely eliminated from the vagina of infected mice 
after prophylactic use of L. casei IMV В-7280 (on the 6th day), B. ani-
malis VKB (on the 9th day) and B. animalis VKL, L. acidophilus IMV 
B-7279 or L. delbrueckii subsp. bulgaricus IMV В-7281 (on the 12th day). 
The number of S. aureus 8325-4 did not decrease in the vagina of mice 
throughout the observation period after prophylactic use of the Labi-
lact® probiotic preparation.  
In the vagina of mice of control group, there was a smaller amount 
of lactobacilli on the 6–12th days and bifidobacteria on the 3–12th days 
compared to intact mice. The number of lactobacilli increased in the 
vagina of infected mice that received L. casei IMV B-7280 or B. anima-
lis VKB on the 1–12th days, B. animalis VKL on the 3–12th days, 
L. delbrueckii subsp. bulgaricus IMV B-7281 on the 6–12th days, 
L. acidophilus IMV B-7279 on the 6–9th days, and the Labilact® probi-
otic preparation only on the 6th day compared to the control group (Fig. 2a).  
The number of bifidobacteria in the vagina was also higher during 
the observation period after administration of probiotic bacteria than in 
the control group, and after prophylactic use of the Labilact® probiotic 
preparation – only on the 6th and 12th days (Fig. 2b).  
The imbalance of vaginal microbiota of staphylococcus infected 
mice against the background of decreasing the amount of lactobacilli 
and bifidobacteria was also confirmed by a significant increase in the 
number of opportunistic microorganisms (aerobic and optional anaerob-
ic microorganisms, streptococci and staphylococci). The number of 
these opportunistic microorganisms at different periods of observation 
varied in the vagina of mice that received probiotic bacteria and the 
Labilact® probiotic preparation as a prophylactic (Table 1). Thus, the 
number of coliform bacteria in the vagina of mice decreased after 
prophylactic use of L. casei IMV B-7280 on the 1–6th and 12th days, 
L. acidophilus IMV B-7279 or B. animalis VKB on the 1st, 3rd and 
12th days, B. animalis VKL or L. delbrueckii subsp. bulgaricus IMV В-
7281 on the 1st and 12th days. In the vagina of infected mice micro-
scopic fungi were detected in a smaller number after prophylactic use of 
L. casei IMV B-7280 or L. delbrueckii subsp. bulgaricus IMV B-7281 
on the 1–12th days, B. animalis VKL on the 6–9th days or B. animalis 
VKB on the 6–12th days. However, the number of microscopic fungi 
increased in the vagina of infected mice after prophylactic use of 
L. acidophilus IMV B-7279 on the 1–12th days, B. animalis VKL – on 
the 3rd and 12th days, B. animalis VKB – on the 3rd day, and Labilact® 
probiotic preparation – on the 3–6th days.  
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b  
Fig. 1. The number of S. aureus 8325-4 colonies in the vagina of infected mice, who had previously received probiotic strains  
of lactobacilli (a) and bifidobacteria (b) as a prophylactic: x ± SD, n = 15  
а  
b  
Fig. 2. The number of lactobacilli (a) and bifidobacteria (b) in the vagina of infected mice, who had previously  
received probiotic strains as a prophylactic: x ± SD, n = 15  
Microbiota of the intestines of mice that received probiotic strains 
intravaginally as a prophylactic. It was shown that the number of lacto-
bacilli in the intestine of infected mice was lower than in intact mice 
during the entire period of observation, and bifidobacteria – on the 6–
12th days (Fig. 4). In the intestinal contents of infected mice the S. au-
reus strain 8325-4 was detected from the 1st day to 12th day, the total 
number of staphylococci also increased (Fig. 3, Table 2).  
The number of aerobic and optional anaerobic microorganisms was 
lower in the intestine of infected mice than in intact animals on the 3rd 
and 9–12th days, and the number of streptococci was lower only on the 
6th day. The number of coliform bacteria was lower than in control on 
the 3–12th days, and the number of microscopic fungi was increased on 
the 1–6th and 12th days. The obtained data confirm total spread of the 
infectious process from the genitourinary system on the gastrointestinal 
tract in infected animals of control group.  
S. aureus 8325-4 strain was not detected in the intestine of infected 
animals during the observation period after prophylactic use of L. casei 
IMV B-7280, B. animalis VKB or B. animalis VKL. Prophylactic use 
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of L. acidophilus IMV В-7279 reduced the number of S. aureus 8325-4 
colonies on the 6–9th days and resulted in complete elimination of the 
pathogen on the 12th day. L. delbrueckii subsp. bulgaricus IMV В-7281, 
as well as the Labilact® probiotic preparation, did not affect the number 
of S. aureus 8325-4 colonies in the intestinal contents of infected mice 
(Fig. 3).  
Table 1  
Spectrum of opportunistic microorganisms in the vagina of infected mice, that previously received probiotic strains as a prophylactic (x ± SD, n = 15)  
Groups of animals Day Number of microorganisms, Lg CFU/mL MPA Baird-Parker-agar KF-Streptococcus agar ENDO Sabouraud agar 
Intact mice – 2.24 ± 0.12 2.51 ± 0.08 2.08 ± 0.04 1.08 ± 0.05 2.07 ± 0.04 
Mice infected  
with S. aureus 8325-4 
  1   3.78 ± 0.13*   4.54 ± 0.08*   3.53 ± 0.05*   1.60 ± 0.04*   2.63 ± 0.05* 
  3   3.82 ± 0.09*   4.30 ± 0.05*   3.45 ± 0.03*   1.48 ± 0.04*   1.48 ± 0.02* 
  6   3.83 ± 0.11*   4.25 ± 0.07*   3.34 ± 0.07*   1.48 ± 0.06* 2.18 ± 0.08 
  9   3.51 ± 0.08*   4.22 ± 0.11*   3.26 ± 0.11*   1.30 ± 0.00*   2.34 ± 0.05* 
12   3.36 ± 0.08*   4.19 ± 0.09*   3.22 ± 0.08*   1.48 ± 0.04* 1.90 ± 0.02 
Received  
L. acidophilus  
ІМV В-7279 
  1    3.00 ± 0.09*•    3.11 ± 0.06*•    2.38 ± 0.02*• < 0.1*•   2.77 ± 0.04* 
  3    3.23 ± 0.04*•    3.02 ± 0.07*•    4.60 ± 0.11*•  1.11 ± 0.02•    3.14 ± 0.06*• 
  6    4.78 ± 0.03*•   4.48 ± 0.12*    4.70 ± 0.09*•    2.12 ± 0.03*•    3.55 ± 0.11*• 
  9    3.09 ± 0.08*•    3.16 ± 0.09*•   3.36 ± 0.06* 1.21 ± 0.01    2.65 ± 0.03*• 
12   3.28 ± 0.11*    3.41 ± 0.11*•    2.95 ± 0.02*•    1.30 ± 0.02*•  2.12 ± 0.02• 
Received  
L. casei  
ІМV В-7280 
  1    3.08 ± 0.04*•    3.00 ± 0.03*•    3.08 ± 0.07*• < 0.1*•    1.30 ± 0.03*• 
  3    3.30 ± 0.06*•    3.30 ± 0.02*•   3.48 ± 0.10* < 0.1*•   1.45 ± 0.01* 
  6    4.95 ± 0.08*•    4.92 ± 0.09*•    4.64 ± 0.14*• < 0.1*•    0.76 ± 0.02*• 
  9    4.68 ± 0.13*•    4.58 ± 0.10*•    4.53 ± 0.06*•   1.32 ± 0.03* < 0.1*• 
12    2.75 ± 0.02*•    3.62 ± 0.07*•    3.76 ± 0.06*• < 0.1*• < 0.1*• 
Received  
B. animalis  
VKL 
  1    2.95 ± 0.05*•  2.34 ± 0.01•    3.09 ± 0.03*• < 0.1*•   2.56 ± 0.03* 
  3  2.34 ± 0.06•    3.96 ± 0.07*•    4.86 ± 0.09*•    2.00 ± 0.05*•  2.04 ± 0.07• 
  6    4.60 ± 0.16*•    4.60 ± 0.09*•    3.90 ± 0.03*•    2.34 ± 0.06*•    1.28 ± 0.08*• 
  9    4.54 ± 0.14*•   4.23 ± 0.14*    4.43 ± 0.09*•    1.78 ± 0.03*•    1.75 ± 0.06*• 
12   3.45 ± 0.08*    3.20 ± 0.03*•   3.26 ± 0.07*    1.30 ± 0.02*•  2.19 ± 0.02• 
Received  
B. animalis  
VKB 
  1  2.38 ± 0.03•  2.60 ± 0.03•    2.90 ± 0.03*• < 0.1*•   2.48 ± 0.03* 
  3    3.04 ± 0.07*•  2.38 ± 0.04•    2.90 ± 0.02*• < 0.1*•    2.64 ± 0.02*• 
  6    3.06 ± 0.08*•  2.48 ± 0.01•    2.38 ± 0.04*•   1.43 ± 0.01* 2.20 ± 0.01 
  9    1.78 ± 0.00*•  2.70 ± 0.04•    3.10 ± 0.06*   1.23 ± 0.02*    1.60 ± 0.03*• 
12  2.30 ± 0.05•  2.56 ± 0.07•    2.38 ± 0.02*• < 0.1*• < 0.1*• 
Received  
L. delbrueckii subsp.  
bulgaricus ІМV В-7281 
  1    1.60 ± 0.00*•    3.05 ± 0.09*•    1.60 ± 0.01*• < 0.1*• < 0.1*• 
  3    3.04 ± 0.07*•    3.09 ± 0.11*•    3.15 ± 0.02*•    2.38 ± 0.07*• < 0.1*• 
  6   3.78 ± 0.08*  2.62 ± 0.02•   3.48 ± 0.09*    2.60 ± 0.03*•    1.43 ± 0.02*• 
  9   3.28 ± 0.05*    2.79 ± 0.04*•    2.34 ± 0.07*•    1.78 ± 0.02*•    1.10 ± 0.01*• 
12    2.73 ± 0.02*•  2.56 ± 0.03•    2.48 ± 0.12*•    1.32 ± 0.03*• < 0.1*• 
Received "Labilact®" 
  1   3.79 ± 0.07*    3.99 ± 0.07*•   3.64 ± 0.07*   2.02 ± 0.05*•    2.34 ± 0.04*• 
  3   3.54 ± 0.06*   4.15 ± 0.09*    3.89 ± 0.11*•    1.98 ± 0.03*•    1.76 ± 0.01*• 
  6    3.17 ± 0.04*•   4.08 ± 0.08*    2.75 ± 0.08*•    1.94 ± 0.04*•    2.55 ± 0.05*• 
  9    3.96 ± 0.10*•   3.97 ± 0.09*    2.45 ± 0.04*•    1.55 ± 0.06*•  2.07 ± 0.02• 
12    3.82 ± 0.09*•   4.12 ± 0.12*    2.96 ± 0.05*•    1.67 ± 0.03*• 1.96 ± 0.01 
Notes: * – P < 0.05 in comparison with indices of intact mice; • – P < 0.05 in comparison with indices of mice of control group.  
а  
 b  
Fig. 3. The number of S. aureus 8325-4 colonies in the feces of infected mice, who had previously received probiotic strains  
of lactobacilli (a) and bifidobacteria (b) as a prophylactic (x ± SD, n = 15)  
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Fig. 4. The number of lactobacilli (a) and bifidobacteria (b) in the feces of infected mice, who had previously  
received probiotic strains as a prophylactic (x ± SD, n = 15)  
Table 2  
Spectrum of opportunistic microorganisms in the feces of infected mice, that previously received probiotic strains as a prophylactic (x ± SD, n = 15)  
Groups of animals Day Number of microorganisms, Lg CFU/mL MPA Baird-Parker-agar KF-Streptococcus agar ENDO Sabouraud agar 
Intact mice – 4.75 ± 0.08 2.87 ± 0.04 3.25 ± 0.05 4.15 ± 0.09 2.77 ± 0.05 
Mice infected with  
S. aureus 8325-4 
  1 4.65 ± 0.06   3.98 ± 0.06* 3.12 ± 0.06 4.11 ± 0.07   2.98 ± 0.04* 
  3   4.32 ± 0.04*   3.65 ± 0.08* 3.05 ± 0.07   3.64 ± 0.07*   3.11 ± 0.06* 
  6 4.98 ± 0.07   3.78 ± 0.11*   2.96 ± 0.02*   3.38 ± 0.08*   3.14 ± 0.08* 
  9   4.13 ± 0.05*   3.42 ± 0.06* 3.09 ± 0.05   3.43 ± 0.02* 2.76 ± 0.08 
12   4.25 ± 0.10*   3.56 ± 0.08* 3.13 ± 0.04   3.58 ± 0.03*   3.04 ± 0.06* 
Received  
L. acidophilus  
ІМV В-7279 
  1 4.51 ± 0.09    3.55 ± 0.05*•    3.78 ± 0.03*• 4.17 ± 0.07 2.78 ± 0.03 
  3   4.29 ± 0.06*   3.78 ± 0.06*    4.25 ± 0.04*•    3.25 ± 0.04*•    3.56 ± 0.02*• 
  6 4.77 ± 0.07    4.22 ± 0.08*•    4.63 ± 0.07*•   3.61 ± 0.09*    4.12 ± 0.05*• 
  9    5.12 ± 0.08*•   3.65 ± 0.04*    4.77 ± 0.08*•   3.45 ± 0.02*    4.55 ± 0.05*• 
12    5.66 ± 0.04*•   3.17 ± 0.05*    4.82 ± 0.05*•  4.05 ± 0.03•    4.59 ± 0.08*• 
Received  
L. casei  
ІМV В-7280 
  1 4.56 ± 0.03    3.15 ± 0.07*• 3.15 ± 0.03 4.05 ± 0.05  2.55 ± 0.07• 
  3   4.73 ± 0.04•   3.46 ± 0.09* 3.02 ± 0.04    3.28 ± 0.06*• 2.87 ± 0.04 
  6 4.81 ± 0.05    3.21 ± 0.08*•   2.98 ± 0.06*   3.45 ± 0.08*    2.43 ± 0.03*• 
  9  4.92 ± 0.03•  2.89 ± 0.03• 3.17 ± 0.02    3.79 ± 0.07*•    2.27 ± 0.02*• 
12  4.98 ± 0.03• 2.86 ± 0.05 3.24 ± 0.07  4.07 ± 0.12•    2.11 ± 0.05*• 
Received  
B. animalis  
VKL 
  1 4.65 ± 0.07  2.65 ± 0.03• 3.26 ± 0.04    4.48 ± 0.04*•  2.61 ± 0.04• 
  3   4.12 ± 0.07*    3.11 ± 0.06*•    3.74 ± 0.05*•   3.45 ± 0.03*    2.12 ± 0.07*• 
  6    3.86 ± 0.09*•   3.22 ± 0.05*  3.24 ± 0.03•  4.20 ± 0.06•    2.10 ± 0.03*• 
  9    3.80 ± 0.04*•  2.98 ± 0.08• 3.12 ± 0.07  4.22 ± 0.07•    1.65 ± 0.01*• 
12    3.44 ± 0.05*• 2.96 ± 0.07    2.54 ± 0.02*•  3.98 ± 0.02•    1.87 ± 0.01*• 
Received  
B. animalis  
VKB 
  1 4.68 ± 0.07    3.22 ± 0.04*•    3.67 ± 0.04*• 4.21 ± 0.03 2.99 ± 0.02 
  3   4.21 ± 0.08*   3.65 ± 0.06* 3.10 ± 0.06   3.77 ± 0.03*   3.15 ± 0.03* 
  6 4.78 ± 0.06    3.19 ± 0.05*•    2.65 ± 0.06*•   3.24 ± 0.03*  2.54 ± 0.05• 
  9   3.91 ± 0.04*  2.86 ± 0.07•    2.84 ± 0.02*•  3.96 ± 0.05•    2.25 ± 0.04*• 
12    3.65 ± 0.05*• 2.65 ± 0.08    2.33 ± 0.03*•  4.11 ± 0.07•    2.11 ± 0.04*• 
Received  
L. delbrueckii subsp.  
bulgaricus ІМV В-7281 
  1    3.28 ± 0.09*•    3.27 ± 0.03*•    3.89 ± 0.06*• 4.22 ± 0.09    2.47 ± 0.06*• 
  3   4.16 ± 0.02*   3.77 ± 0.02*    4.14 ± 0.08*•  3.98 ± 0.06•    3.69 ± 0.07*• 
  6    3.75 ± 0.07*•   3.86 ± 0.08*    4.26 ± 0.09*•    3.74 ± 0.07*•    4.10 ± 0.08*• 
  9  4.79 ± 0.09•    4.17 ± 0.09*•    4.51 ± 0.05*•   3.45 ± 0.09*    5.47 ± 0.17*• 
12    5.27 ± 0.05*•   4.25 ± 0.09*    4.89 ± 0.07*•    3.23 ± 0.04*•    6.17 ± 0.29*• 
Received "Labilact®" 
  1 4.52 ± 0.09   3.83 ± 0.07* 3.24 ± 0.05 4.23 ± 0.07   3.22 ± 0.12* 
  3 4.59 ± 0.12   3.77 ± 0.08* 3.27 ± 0.03   3.72 ± 0.04*   3.17 ± 0.08* 
  6 4.57 ± 0.12   3.86 ± 0.05* 3.14 ± 0.08   3.49 ± 0.05*   3.10 ± 0.09* 
  9   4.22 ± 0.08*   3.58 ± 0.12* 3.22 ± 0.11   3.56 ± 0.08*   2.92 ± 0.06* 
12   4.39 ± 0.11*   3.65 ± 0.06* 3.33 ± 0.09   3.67 ± 0.03*   3.25 ± 0.07* 
Note: see Table 1.  
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After prophylactic use of L. casei IMV B-7280, B. animalis VKL 
and B. animalis VKB the number of lactobacilli in the intestinal con-
tents of infected animals increased on the 1–12th days, and after use of 
L. acidophilus IMV B-7279 and L. delbrueckii subsp. bulgaricus IMV В-
7281 – on the 3–12th days (Fig. 4a). The Labilact® probiotic preparation 
did not affect the amount of lactobacilli in the intestines of infected mice.  
The amount of bifidobacteria in the intestine of infected mice in-
creased after use of L. casei IMV B-7280, B. animalis VKL and B. ani-
malis VKB on the 1–12th days, L. acidophilus IMV B-7279 – on the 9–
12th days, and L. delbrueckii subsp. bulgaricus IMV В-7281 – on the 
3–6th days (Fig. 4b). The Labilact® drug did not affect the amount of 
bifidobacteria in the intestines of infected mice.  
The number of aerobic and optional anaerobic bacteria in the intes-
tine of infected mice increased after administration of L. casei IMV B-
7280 on the 3rd and 9–12th days and L. acidophilus IMV B-7279 or 
L. delbrueckii subsp. bulgaricus IMV B-7281 on the 9–12th days, but 
decreased after use of B. animalis VKL on the 6–12th days, B. animalis 
VKB on the 12th day and L. delbrueckii subsp. bulgaricus IMV В-7281 
on the 6th day. L. casei IMV B-7280 or B. animalis VKB reduced the 
number of staphylococci on the 1st and 6–9th days, B. animalis VKL – 
on the 1–3rd and 9th days, and L. acidophilus IMV B-7279 or L. del-
brueckii subsp. bulgaricus IMV В-7281 – on the 1st day, whereas 
L. acidophilus IMV В-7279 and L. delbrueckii subsp. bulgaricus IMV 
B-7281 increased the number of staphylococci on the 6th and 9th days, 
respectively. The number of streptococci increased in different periods 
of observation after use of L. acidophilus IMV-7279, L. delbrueckii 
subsp. bulgaricus IMV B-728, B. animalis VKL or B. animalis VKB.  
The number of coliform bacteria in the intestine of infected mice af-
ter administration of B. animalis VKL on the 1st and 6–12th days, 
L. casei IMV B-7280 or B. animalis VKB on the 9–12th days, L. del-
brueckii subsp. bulgaricus IMV В-7281 – on the 3–6th days, and 
L. acidophilus IMV В-7279 – only on the 12th day was increased, but 
was decreased after administration of L. casei IMV В-7280 or L. acido-
philus ІМV В-7279 on the 3rd day and L. delbrueckii subsp. bulgaricus 
IMV В-7281 – on the 12th day.  
 
Discussion  
 
Currently medical and scientific community considers vaginal mi-
crobiota as a complete "ecosystem" (Pascual et al., 2008) which, apart 
from many other functions, causes direct or indirect antagonistic action 
against pathogens that cause genitourinary tract infections, and also 
affects the development of the immune response (Mumtaz et al., 2008; 
Verstraelen, 2008; Frey Tirri, 2011; Thomas-White et al., 2015). In 
addition, according to the latest data, the imbalance of vaginal microbi-
ota can cause a range of diseases, including functional disorders of the 
pelvic organs, pathology of immune, neuroendocrine, gastrointestinal and 
nervous systems (Brubaker & Wolfe, 2017; Wood & Anger, 2014).  
While some doctors and researchers are still skeptical about the use 
of probiotics as preparations in monotherapy for infectious diseases of 
different nature, there is increasing evidence of using probiotics for 
therapeutic, and especially for prophylactic purpose (Barbés & Boris, 
1999). So, recent studies by Cianci et al. (2018) have proven the possi-
bility of preventing the development of vaginitis in women receiving 
systemic antibiotic therapy, with the prophylactic use of the L. planta-
rum P 17630 probiotic strain. Recine et al. (2015) demonstrated the 
promising use of the L. rhamnosus BMX 54 strain to prevent the devel-
opment of bacterial vaginosis. Murina et al. (2014) had similar conclu-
sions after studying the effectiveness of L. fermentum LF10 and L. 
acidophilus LA02 strains to prevent the development of candidiasis.  
There are also comprehensive meta-analyzes that systematize do-
zens of similar studies and demonstrate the promising use of representa-
tives of saprophytic microbiota to prevent the development of infectious 
diseases of the urogenital tract and bacterial vaginitis (Grin et al., 2013) 
in clinical practice, in particular during the preparation for the planned 
pregnancy. Our results are consistent with the conclusions given by 
other researchers and confirm the promising use of probiotic strains of 
lactobacilli and bifidobacteria for the prevention and treatment of infec-
tious and inflammatory diseases of the genitourinary system. In the 
present study, probiotic strain L. casei IMV B-7280, B. animalis VKL 
and B. animalis VKB were most effective for prevention of staphylo-
coccal vaginitis as far as they significantly accelerate the elimination of 
S. aureus 8325-4 strain from vagina of infected mice, prevent the spread 
of the pathogen to the intestines and caused normalization of vaginal 
and intestinal microbiota by increasing the amount of lactobacilli and 
bifidobacteria and reducing the number of opportunistic bacteria.  
According to the latest data, even a minor violation of vaginal micro-
biota should be considered as a complete illness (Reid, 2017) with a sig-
nificant spectrum of potentially adverse variants of development, the 
importance of creation of new tools for prevention and treatment of this 
condition at an early stage is difficult to overestimate. In addition, the fact 
that the disorder in the composition of normal vaginal microbiota and the 
decrease in the number of saprophytic lactobacilli and bifidobacteria sig-
nificantly increases the risk of infection with sexually transmitted diseases, 
including HIV, is already proven, therefore the vaginal use of probiotic 
strains of bacteria can be considered as direct an effective prophylactic tool 
to prevent the spread of these diseases (McMillan et al., 2015).  
Therefore, the further development of modern probiotics based on 
highly active strains of lactobacilli and bifidobacteria with a wide range 
of therapeutic and prophylactic actions, in particular on the basis of 
L. casei IMV B-7280, B. animalis VKL and B. animalis VKB probiotic 
strains, may become a new direction not only in the treatment of infec-
tious and inflammatory diseases of the genitourinary system, but also 
one of the elements of an integrated approach to improving the quality 
and life expectancy of people.  
 
Conclusions  
 
It was found that infection of mice with S. aureus 8325-4 strain 
caused an imbalance of vaginal and intestinal microbiota, as evidenced 
by an increase in the number of opportunistic microorganisms and a 
decrease in the amount of lactobacilli and bifidobacteria. Administration 
of L. casei IMV B-7280, B. animalis VKL and B. animalis VKB probi-
otic strains before infection with S. aureus 8325-4 had a significant 
effect on the microbiota spectrum of the vagina and intestine: an in-
crease in the amount of lactobacilli and bifidobacteria was observed 
with a decrease in the number of opportunistic microorganisms. Rapid 
elimination of S. aureus 8325-4 from the vagina and prevention of the 
spread of infection to the intestine was also observed after use of these 
probiotic strains. Preventive action of L. acidophilus IMV B-7279 and 
L. delbrueckii subsp. bulgaricus IMV B-7281 for bacterial vaginitis in 
mice was less effective. Target probiotic strains L. casei IMV B-7280, 
B. animalis VKL and B. animalis VKB are promising for the creation 
of highly effective novel probiotic drugs that can be used for directed 
prevention of infectious and inflammatory diseases of the genitourinary 
system caused by pathogenic and opportunistic microorganisms.  
 
The research work was partially carried out under the project titled “Development 
of probiotics for the prevention and treatment of infectious-inflammatory dise-
ases” (DZ/48-2018) that was financed by the Ministry of Education and Science 
of Ukraine. The funder had no influence of study design, data collection and 
analysis, decision to publish or preparation of the manuscript.  
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